Objective: To determine whether genotypes at 2 major loci associated with late age-related macular degeneration (AMD), complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), influence the relative benefits of Age-Related Eye Disease Study (AREDS) supplements.
b-carotene), zinc or a combination.
Main Outcome Measures:
The influence of the genotype on the relative treatment response to the randomized components of the AREDS supplement, measured as progression to late AMD.
Results: Of the 1237 genotyped AREDS participants of white ethnicity, late AMD developed in 385 (31.1%) during the mean follow-up of 6.6 years. As previously demonstrated, CFH genotype (P ¼ 0.005), ARMS2 (P< 0.0001), and supplement were associated individually with progression to late AMD. An interaction analysis found no evidence that the relative benefits of AREDS supplementation varied by genotype. Analysis of (1) CFH rs1061170 and rs1410996 combined with ARMS2 rs10490924 with the 4 randomly assigned arms of AREDS supplement and (2) analysis of the combination of CFH rs412852 and rs3766405 with ARMS2 c.372_815del443ins54 with the AREDS components resulted in no interaction (P ¼ 0.06 and P ¼ 0.45, respectively, before multiplicity adjustment).
Conclusions: The AREDS supplements reduced the rate of AMD progression across all genotype groups. Furthermore, the genotypes at the CFH and ARMS2 loci did not statistically significantly alter the benefits of AREDS supplements. Genetic testing remains a valuable research tool, but these analyses suggest it provides no benefits in managing nutritional supplementation for patients at risk of late AMD. Ophthalmology 2014;-:1e8 ª 2014 by the American Academy of Ophthalmology. *Supplemental material is available at www.aaojournal.org.
Age-related macular degeneration (AMD) is the leading cause of blindness in the United States, with nearly 2 million late AMD cases and 8 million intermediate AMD cases estimated in 2004. 1 With increased population longevity, the numbers of individuals affected with AMD are projected to double by 2024. 1 The Age-Related Eye Disease Study (AREDS) followed up persons with intermediate AMD (large drusen or extensive medium drusen) or late AMD in only 1 eye at enrollment and demonstrated that, over 5 years, the AREDS supplements, consisting of antioxidants (vitamin E, vitamin C, and b-carotene) and zinc (plus copper), reduced the risk of development of late AMD, especially neovascular AMD, by 25% ( Fig 1A) . 2 Age-related macular degeneration is a complex disease with both heritable and environmental risks. Epidemiologic studies have revealed the exponential increase in prevalence of AMD with age, an increase in risk conferred by smoking, a protective effect of fatty fish and green leafy vegetable consumption, and a less consistent association with body mass index and hypertension.
3e9 Genetic studies have identified 19 susceptibility loci that seem to explain more than 50% of the risk of AMD developing. 10 These studies point to biological pathways that may contribute to AMD pathogenesis; these include alternative complement activation, high-density lipoprotein cholesterol transport and metabolism, extracellular matrix integrity and cell adhesion, and angiogenesis. 3 An important question is whether knowledge of individual risk genotypes could inform the choice of therapeutic strategy among at-risk individuals, as happens now in some areas of medicine. For example, in oncology, information on genetic variants that predict successful responses to therapy (or adverse events) has led to genetically informed treatment strategies. 11, 12 Numerous studies have evaluated the association of genetic testing and treatment with antievascular endothelial growth factor drugs for neovascular AMD with retrospective analyses.
13e18 These have been studies with varying outcome variables and durations, resulting in no clear consensus about this association. Genetic information has not added to clinical factors such as visual acuity at baseline, lesion size, age, and interval between symptoms and treatment that seem to be important in determining the visual outcomes after treatment. 19 Five years ago, Klein et al 20 evaluated possible genetic predictors of response to treatment with the AREDS supplement. Included in the analyses were all 867 AREDS participants with intermediate AMD (large drusen or extensive medium drusen in 1 or both eyes) or late AMD in 1 eye and for whom DNA samples were available. The baseline AMD severity levels in these 867 individuals matched guidelines for therapy with the AREDS supplement. Single nucleotide polymorphisms (SNPs) in the CFH (p.Y402H, rs1061170) and ARMS2 (p.A69S, rs10490924) genes were genotyped. Evidence for a possible interaction between the CFH genotype and the benefit of treatment with antioxidants plus zinc was detected. Individuals with the homozygous nonrisk genotype for CFH (TT) had a greater reduction in progression to late AMD than those with the homozygous risk genotype (CC), 68% versus 11% (P ¼ 0.03). There was no significant interaction between ARMS2 p.A69S genotype and treatment with any AREDS supplement regimen. Results of their study led Klein et al 20 to conclude that AREDS supplements were associated with a reduction in progression to late AMD in all genotypic groups and that neither antioxidant alone nor zinc alone was superior to the combination of antioxidants and zinc in reducing progression to AMD in any genetic group. Although evidence for differences in treatment response to AREDS supplements for individuals with different genotypes was observed, the results for all groups were in the direction of a treatment benefit. These findings, together with the need for replication data and corroborative functional studies and the lack of available alternative interventions, led the authors to conclude that routine genetic testing was not indicated before prescribing AREDS supplements.
A more recent study by Awh et al 21 suggested that the administration of AREDS supplements should be modified in certain subgroups of patients based on their CFH and ARMS2 genotypes. The present study examined a subset of the AREDS participants (n ¼ 995) from whom DNA was collected. We re-evaluated this suggestion in an unplanned retrospective analysis of a larger cohort of AREDS participants (from 1237 to 1413, depending on the SNPs) with available DNA and who were at high risk of late AMD developing.
Methods

Study Population
The AREDS design was reported previously. 22 We summarize the study details that are relevant to this report. Participants with varying severities of AMD were enrolled in 11 retinal specialty clinics. Each clinical center obtained institutional review board approval for the study protocol, and all participants signed the study's informed consent form. The study adhered to the tenets of the Declaration of Helsinki and this study was conducted prior to the existence of the Health Insurance Portability and Accountability Act (HIPAA). Included in these analyses were 1237 participants who had available DNA and were considered at high risk of progression to late AMD. We confined our analyses to those participants with intermediate AMD in 1 or both eyes (n ¼ 832; AREDS AMD category 3) or late AMD in 1 eye (n ¼ 405; AREDS AMD category 4). It is for these groups that therapy with AREDS supplements is currently recommended. The participants had been assigned randomly to 1 of 4 treatment groups: antioxidants plus zinc, antioxidants, zinc, or placebo. The antioxidants consisted of vitamin C (500 mg), vitamin E (400 IU), and b-carotene (15 mg). Zinc was given as zinc oxide (80 mg) along with copper as cupric oxide (2 mg).
Baseline data were collected, including age, race, gender, education, smoking history, body mass index, and medical history. Stereoscopic fundus photographs of the macula, obtained at baseline and annually beginning 2 years after enrollment, were graded centrally using standardized grading procedures. The participants were followed up for the clinical trial from 1992 until 2001. Additional follow-up through 2005 was conducted as an observational study. Our analyses were confined only to the period of the randomized controlled clinical trial until 2001. Additional analyses, including events after the conclusion of the trial, did not alter our conclusions.
Outcomes
The primary outcome for this report was the interaction between the genotypes and treatment responses to the antioxidants and zinc, evaluated by the progression to late AMD. Disease progression was determined from (1) the grading of the stereoscopic fundus photographs for the presence of central geographic atrophy or retinal features of choroidal neovascularization or (2) history of treatment for late AMD after study enrollment.
Genotyping
The 1237 AREDS participants were genotyped for common SNPs at the CFH locus (rs1061170 and rs1410996) and ARMS2 (rs10490924) using the TaqMan assay (Applied Biosystems, Foster City, CA) method. To reduce the multiple testing burden, genotypes of the 2 CFH SNPs, rs1061170 and rs1410996, were grouped into 3 risk categoriesdlow risk, medium risk, and high riskdaccording to their combined risk effect. This was based on a separate analysis of 1717 AMD nonoverlapping cases and 1150 controls from a published genome-wide association study (GWAS) study (Table 1 , available at www.aaojournal.org). 23 We repeated analyses using 2 other CFH SNPs, rs412852 and rs3766405 (n ¼ 1413), to mimic the recently reported analyses 14 ( 
Statistical Plan
Analyses were performed using the Cox proportional hazards model to predict progression to late AMD (neovascular or central geographic atrophy). The models included age (1 degree of freedom [df]), gender (1 df), smoking status (2 df), baseline AMD severity (1 df), AREDS treatment (3 df), and either CFH (2 df) or ARMS2 (2 df) or the combination of CFH and ARMS2 (8 df). Table 3 (available at www.aaojournal.org) displays the dfs used in each of the models presented in this current study. The treatment by genotype interaction was included in each model. We particularly focused on evaluating evidence that interaction between treatment with AREDS supplements in the 4 randomly assigned arms (placebo, antioxidants, zinc, and antioxidants and zinc) and the genetic risk alleles (at CFH and ARMS2) may affect the progression to late AMD. Two separate sets of analyses were conducted for interaction of AREDS treatments with CFH and ARMS2 variants. The first set of analyses included the most commonly known and studied risk alleles: a 2 SNP CFH haplotype comprising rs1061170 and rs1410996 and the rs10490924 SNP in the ARMS2. A second set of analyses evaluated the variants used in the study by Awh et al 21 : an alternate 2 SNP CFH haplotype (rs412852 and rs3766405) and the ARMS2 deletion c.372_815del443ins54.
Because the study design was a 2Â2 factorial, main effects analyses also were conducted by comparing antioxidants versus no antioxidants and zinc versus no zinc with each genotype group (results are found in the supplementary materials because these results are not particularly informative in deciding whether to use antioxidants or zinc alone compared with the combination). To facilitate comparison with the study by Awh et al, 21 pairwise comparisons were conducted to evaluate evidence for benefit of each supplementation regimen as a function of each genotype. For example, for each of the 3 levels of the CFH haplotype (low risk, medium risk, high risk), we evaluated 3 supplementation regimens (antioxidants vs. placebo, zinc vs. placebo, and combination of antioxidant and zinc vs. placebo), resulting in 9 different pairwise comparisons. These were expressed as hazard ratios with 99.9% confidence intervals, using a Bonferroni-corrected P value (P < 0.001) for the determination of statistical significance because 45 comparisons in total were conducted: 9 tests for each combination of the 3 CFH levels for each of the 3 AREDS treatments and, similarly, 9 tests for the ARMS2 loci. For the combination of CFH and ARMS2 and the 3 AREDS treatments, there were 27 tests. This resulted in a total of 45 tests.
Results
Characteristics of the 1237 AREDS participants are summarized in Table 4 . The mean age was 69 years; of these, 59% were female, and 55% were former or current smokers. Baseline characteristics and the distribution of the genotypes at CFH (rs1061170 and rs1410996) and ARMS2 (rs10490924) loci both were similar across the 4 AREDS supplement treatment allocations: P ¼ 0.87 and P ¼ 0.79 (chi-square test), respectively ( Table 4 ). The combined genotypes of CFH (rs412852 and rs3766405) and ARMS2 (c. 372_815del443ins54; n ¼ 1413) also were distributed similarly across the AREDS treatment groups: P ¼ 0.93 and P ¼ 0.98 (chi-square test), respectively ( Table 4 ). The call rate for each SNP analyzed here was greater than 98%. The rates of progression to late AMD by the genetic risk, ranging from low-risk (no risk alleles) to high-risk (homozygous) genotypes, demonstrated an increasing rate with higher-risk alleles (CFH [rs1061170 and rs1410996]: 17.9%, 25.7%, 38.6%; ARMS2: 18.5%, 35.9%, 48.3%; for low, medium, and high risk, respectively).
We also compared the rates of progression to late AMD among the AREDS participants with (n ¼ 1237) or without (n ¼ 1325) DNA (Table 5 , available at www.aaojournal.org) and found no statistically significant differences (P ¼ 0.96 Cochran-Mantel-Haenszel test). Table 6 (available at www.aaojournal.org) shows that the highest rates of progression to late AMD were seen in those groups with the heterozygous and homozygous risk genotypes.
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Main Analyses of Influence of Combination CFH and ARMS2 Genotypes on Age-Related Eye Disease Study Supplement Treatment Effect
The Cox proportional hazards model evaluating the interaction of genotype of the combination of CFH (rs1061170 and rs1410996) and ARMS2 (rs10490924) and treatment with the 4 different randomized arms of AREDS trialdplacebo, antioxidant, zinc, and antioxidant plus zincdresulted in no statistically significant interaction (P ¼ 0.06). To be statistically significant with the Bonferroni correction, the P value needs to be less than 0.001. Given this lack of statistical significance in the overall analyses, we would usually terminate our investigation at this point. However, as stated a priori and because of recent interest, we also carried out subgroup analyses. Figure 1B demonstrates the results of the pairwise comparison of the components of the AREDS supplements antioxidant and zinc, antioxidant alone, and zinc alone with placebo for CFH (rs1061170 and rs1410996) combined with ARMS2 (rs10490924). Again, none of these results reached statistical significance, and all were consistent with treatment benefit. As noted in the methods, our analysis involves a total of 45 comparisons and a corresponding Bonferroni threshold P value of less than 0.001.
Similar analyses using alternate genetic variants for CFH (rs412852 and rs3766405) and ARMS2 (indel: c.372_815del443ins54), an analysis designed to mimic the study conducted by Awh et al, 21 also demonstrate no statistically significant interaction between treatment effect and genotype (P ¼ 0.45; Fig 1C) . Similar pairwise comparisons using these genotypes also were not statistically significant (Fig 1C) .
Analyses of Influence of CFH and ARMS2 Genotypes Individually on Age-Related Eye Disease Study Supplement
The Cox proportional hazards models evaluating the interaction of CFH (rs1061170 and rs1410996), ARMS2 (rs10490924), CFH (rs412852 and rs3766405), and ARMS2 (indel: c.372_ 815del443ins54), each individually with treatment with the 4 different randomized arms of AREDS trial, resulted in no statistically significant interaction (Fig 2AeD, available at www. aaojournal.org); these figures also showed no statistically significant pairwise comparisons in these subgroups.
Analyses of Influence of CFH and ARMS2 on the Main Effects of Antioxidants and Zinc
The Cox proportional hazard models evaluating the influence of CFH (rs1061170 and rs1410996), ARMS2 (rs10490924), CFH (rs412852 and rs3766405), and ARMS2 (indel: c.372_ 815del443ins54), individually on the treatment effects of the main effects of antioxidants (antioxidants vs. no antioxidants), demonstrated no statistically significant interactions (Fig 3AeD, available at www.aaojournal.org). Similar analyses were conducted for the main effects of zinc (zinc vs. no zinc) and resulted in no consistent statistically significant interactions (Fig 4AeD, available Fig 5B, 5D , available at www. aaojournal.org). Again, all these analyses did not result in consistent statistically significant interactions.
Discussion
We found no statistically significant interaction between CFH and ARMS2 genotype and treatment with AREDS supplements, as determined by progression to late AMD in these retrospective analyses of the randomized controlled clinical trial. The findings presented here do not support the conclusions of Awh et al 21 that recommended altering the composition of AREDS supplements based on an individual's CFH and ARMS2 genotypes, and are instead similar to the recommendations of Klein et al 20 against routine genotyping before prescribing AREDS supplements. What can account for the differences between these current results and the Awh et al 21 report? Differences in subgroup analyses are not uncommon, as such analyses are fraught with difficulties, including insufficient power, multiple comparisons, and possible confounders. The increase in sample size with an accompanying increase in event rates in the current study probably accounts for some of the differences.
A repeat analysis using exactly the same CFH and ARMS2 SNPs as those used by Awh et al 21 also did not alter our conclusions. We did not expect the use of the different SNPs at CFH to alter the conclusions greatly because these SNPs are highly correlated as a result of strong linkage disequilibrium. The statistical methods were somewhat different in the 2 studies because we analyzed the randomized arms for an overall interaction term, whereas previous studies provided the results from subgroup analyses by treatment versus placebo and main effects, and because we used a more stringent Bonferroni adjustment to account appropriately for multiple comparisons before declaring significance. We have repeated the analyses with several SNPs in CFH (rs412852, rs3766405, rs10737680, rs1061170, and rs1410996) and used 2 variants in ARMS2 (rs10490924, 372_815del443ins54); however, none of the results was statistically significant.
We also confined our data to the randomized portion to the study up to 2001 because the participants assigned to the placebo group were recommended to take the AREDS supplements in the follow-up portion of the study from 2001 through 2005. They were no longer in a randomized comparison. Awh et al, 21 however, also conducted the analyses using a small sample size throughout the entire follow-up period, both the complete clinical trial and the observation follow-up. Table 7 (available at www.aaojournal.org) shows the imbalance in event rates to late AMD in the 2 groups of AREDS participants with and without DNA samples when the analyses are extended throughout the study, 1992 through 2005. This also may account for their findings, which were different from the results of the current study.
An important limitation of the current study and the 2 previous reports is the lack of power to find an interaction. The number of individuals examined in each of the studies evaluating genetic interaction ranged from 895 to 1413 participants, and the projected sample size in the original AREDS was nearly 4000 to evaluate the modest treatment effect of the AREDS formulation in persons at risk, assuming no interaction between the components of therapy or with other variables. 22 Given that this is a randomized trial that will not be repeated and the additional collection of DNA samples from the AREDS cohort is not feasible, we likely will not increase the power of such analyses. The AgeRelated Eye Disease Study 2 (AREDS2), which addresses a different clinical question regarding adding nutritional supplements of lutein and zeaxanthin, omega-3 fatty acids, or a combination thereof will not provide information on this subject.
As in the case of the initial genetic associations reported with response to treatment with intravitreal bevacizumab and ranibizumab, 13 further analyses have failed to replicate the initial findings. Genetic association analyses are vulnerable to all the problems associated with subgroup analyses, and they especially require replication before widespread clinical recommendations are implemented. Because these data are retrospective, one also should be cautious about making clinical recommendations, even if the findings had been statistically significant. Such analyses generally are thought of as hypothesis generating, requiring independent verification before implementation, because they often are chance observations that cannot be replicated.
It is exciting to think that we are rapidly moving toward personalized medicine for AMD, as in other diseases such as breast cancer or leukemia; however, much work remains to be done before genetic knowledge can be applied for disease management. 25 The treatment with AREDS supplement is demonstrated to be effective when using both antioxidants and zinc together across all genetic groups defined on the basis of CFH and ARMS2 genotype. We therefore continue to recommend the use of AREDS supplements for patients at risk of late AMD developing. At this stage, genetic testing does not seem helpful in improving treatment with AREDS supplements. Further investigations using a large set of genetic risk variants and with larger cohorts (case control or family based) eventually may allow us to make more definitive recommendations for genetic diagnosis and management of AMD patients.
